Earlier this week,
VolitionRx reported significant results from a pilot study of use of its NuQ®
tests for diagnosis of prostate cancer. The results of the trial showed that
the tests were able to detect approximately 80 percent of prostate cancer
cases. Notably, they also showed that in addition to their high prostate cancer
detection rate, the company’s tests are also able to differentiate between
colorectal and prostate cancer.
“This is a very exciting
outcome for us as we continue the development of our NuQ tests,” said Dr. Jake
Micallef, Chief Scientific Officer at VolitionRx. “To have proof that with the
right panel combination, NuQ tests can distinguish between different types of
cancer as well as healthy samples, is just what we’ve been working towards.
Detection of two major cancers with a blood test is a major milestone and a
sound basis on which to investigate further cancers for panels of NuQ tests
that detect and distinguish cancer diseases.”
The NuQ tests are able to
make this distinction via detection of levels of epigenetically altered
circulating nucleosomes in each sample, the structure of which Volition has
found to be different in the two different types of cancer. As an illustration,
VolitionRx mentions that the “levels of circulating nucleosomes containing
H3K9(Me)3 were elevated in colorectal cancer, but supressed in prostate
cancer”. This is an indicator of the NuQ ELISA tests’ ability to detect both
cancer types.
Dr. Micallef will be
presenting a poster at The International Society of Oncology and Biomarkers
Congress (ISOBM) in Barcelona, Spain. There he will share results of the latest
study into the effectiveness of NuQ® assays as an initial screening tool in
detecting colorectal and now prostate cancer.
VolitionRx is carrying out
several clinical trials on the effectiveness of the NuQ® assays as a cancer
diagnostic tool:
• A 4,800-patient retrospective study and an 11,000 patient
prospective study into colorectal cancer at Hvidovre Hospital, University of
Copenhagen, Denmark.
• A 2,000-patient prospective study that involves patients
with the 20 most prevalent cancers at University Hospital in Bonn, Germany.
• A 250-patient study into colorectal cancer at CHU-UCL Mont
Godinne Hospital, Belgium.
Another recent trial
documented that VolitionRx’s NuQ assays were able to detect over 85 percent of
colorectal cancer cases with over 85 percent specificity. This earlier study
had taken samples from healthy subjects as well as patients recently diagnosed with
colorectal cancer.
A life sciences company
focused on developing blood-based diagnostic tests for different types of
cancer, VolitionRx seeks to provide diagnostic tests as common and easy-to-use
as mainstream as diabetes and cholesterol tests for patient and doctor use.
For more information, visit:
www.volitionrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
